Comment: Serotonin syndrome and 5-HT2A antagonism [4]

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1143-1144

  Isbister, Geoffrey K ^a   Dawson, Andrew ^a   Whtye, Ian M ^a  

^a NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; CHLORPROMAZINE; CLOMIPRAMINE; CLORGYLINE; CLOZAPINE; CYPROHEPTADINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; PROPRANOLOL; RISPERIDONE; RITANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

CLINICAL FEATURE; HUMAN; HYPERPYREXIA; LETTER; NONHUMAN; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ANIMALS; CLOMIPRAMINE; CLOZAPINE; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0034835824     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10218a     Document Type: Letter

References (11)

1. Serotonin syndrome: History and risk
2. The serotonin syndrome
3. Serotonin syndrome complicating treatment of recurrent depression
4. The serotonin syndrome and its treatment
5. Risperidone counteracts lethality in an animal model of the serotonin syndrome
6. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome
7. Treatment of the serotonin syndrome with cyproheptadine
8. Cyproheptadine: A potent in vivo serotonin antagonist
9. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds
10. Successful treatment of serotonin syndrome with chlorpromazine
11. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine